Revisiting the PARTNER 3 trial: are 5-year hemodynamic findings enough to settle the debate in low-risk aortic...

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Medical Imaging

Background:

• The PARTNER 3 trial evaluated transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in low-surgical-risk patients.
• Echocardiographic findings assess long-term valve performance and patient outcomes.

Purpose of the Study:

• To review 5-year echocardiographic data from the PARTNER 3 trial.
• To compare long-term outcomes of TAVR and SAVR in low-risk patient populations.

Main Methods:

• Analysis of 5-year echocardiographic findings from the PARTNER 3 trial.
• Review of companion publications on late mortality and patient survival.

Main Results:

• TAVR demonstrated early hemodynamic advantages, including improved right ventricular-pulmonary artery coupling and reduced valvulo-arterial impedance.
• These early benefits did not consistently lead to superior long-term outcomes for TAVR.
• Emerging data suggest potential late mortality in the TAVR group, with comparable early results to SAVR.

Conclusions:

• Long-term survival is a critical factor for guiding treatment decisions in younger, low-risk patients undergoing aortic valve replacement.
• Early hemodynamic improvements with TAVR may not outweigh the importance of long-term survival.
• Treatment decisions should prioritize sustained patient survival over short-term hemodynamic metrics.